Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC3191 Ly-465608
Novel potent and selective dual PPARalpha/gamma agonist
More description
DCC3190 Ly456236 Hydrochloride
Selective mGlu1 receptor antagonist
More description
DCC3189 Ly451646
AMPA receptor potentiator
More description
DCC3188 Ly444711
Orally active ghrelin agonist, bindjng with high affinity to and being a potent activator of the growth hormone secretagogue receptor 1a (GHS-R1a) receptor
More description
DCC3187 Ly-395153
Allosteric modulator of AMPA receptors
More description
DCC3186 Ly392098
AMPA receptor potentiator
More description
DCC3185 Ly382884
Selective GluR5 kainate receptor antagonist
More description
DCC3184 Ly339434
Potent GluR5 kainate receptor agonist
More description
DCC3183 Ly-333531 Mesylate
Potent and selective inhibitor of PKCβI and PKCβII
More description
DCC3182 Ly2979165 Ammonium Salt
Novel highly potent and selective agonist of metabotropic glutamate (mGlu) receptors 2 and 3
More description
DCC3180 Ly2934747
Novel, potent, and systemically bioavailable mGlu2/3 receptor agonist, exhibiting both antipsychotic and analgesic properties in vivo
More description
DCC3179 ly2886721 Hydrochloride
Orally active cell-permeable inhibitor of human
More description
DCC3178 Ly-278584
Potent 5-HT3 serotonin receptor antagonist
More description
DCC3177 Ly2389575
Selective negative allosteric modulator of mGlu3
More description
DCC3176 Ly-231617
Potent antioxidant, being cytoprotective in models of focal and global cerebral ischemia
More description
DCC3175 ly-2140023
Novel mGlu2/3 receptor agonist; Prodrug of LY-404039
More description
DCC3174 ly-2121260
Novel glucokinase activator (GKA)
More description
DCC3173 Ly2048978
Novel, potent, orally-bioavailable kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders
More description
DCC3172 Ly2019-006
Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 1526.00 ± 0.87 nM, 1165.00 ± 1.18 nM, respectively
More description
DCC3171 Ly2019-005
Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 424.40 ± 1.31 nM, 378.80 ± 1.20 nM, respectively
More description
DCC3170 Lxy6090
Novel potent HIF-1 inhibitor, also downregulating the protein level of HIF-1alpha, which depended on von Hippel-Lindau for proteasome degradation, showing in vivo anticancer efficacy by decreasing the HIF-1alpha expression in nude mice bearing MX-1 tumor
More description
DCC3169 Lxy6006
Novel Manassantin A Derivative, Inhibiting Hypoxia-Inducible Factor 1 and Tumor Growth
More description
DCC3168 lxrβ-agonist-19
Novel selective LXRβ agonist, reducing total brain Aβ
More description
DCC3167 Lx7101 Hydrochloride
Novel Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
More description
DCC3166 Luminolate (luminol Sodium Salt)
Immune modulator with SARS-CoV-2 antiviral activity via a multi-target mechanism including localized, self-limiting reactive oxygen species (ROS) scavenging activities that were demonstrated in a model of lipopolysaccharide (LPS)-induced joint inflammatio
More description
DCC3165 Luminespib Mesylate
Novel inhibitor of heat shock protein 90 (Hsp90)
More description
DCC3164 Lugdunin
Thiazolidine-containing cyclic peptide antibiotic, suppressing growth of species of disease-causing bacteria in that part of the human microbiome
More description
DCC3163 Luf-6258
Hybrid ortho/allosteric ligand of the adenosine A(1) receptor
More description
DCC3162 Luf-6056
Human adenosine A1 receptor antagonist
More description
DCC3161 Luf-5764
A1 adenosine receptor antagonist
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X